CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

Abstract Background Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen...

Full description

Bibliographic Details
Main Authors: Jennifer D. Brooks, Elizabeth A. Comen, Anne S. Reiner, Irene Orlow, Siok F. Leong, Xiaolin Liang, Lene Mellemkjær, Julia A. Knight, Charles F. Lynch, Esther M. John, Leslie Bernstein, Meghan Woods, David R. Doody, The WECARE Study collaborative group, Kathleen E. Malone, Jonine L. Bernstein
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Breast Cancer Research
Subjects:
Contralateral breast cancer
Tamoxifen
CYP2D6
Online Access:http://link.springer.com/article/10.1186/s13058-018-1083-y

Internet

http://link.springer.com/article/10.1186/s13058-018-1083-y

Similar Items